Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV
HIV Medicine · 2025
DOI: 10.1111/hiv.70057 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift HIV Medicine, 2025. Verfasst von Kyle Ring und 4 weiteren Autor:innen. Beteiligte Einrichtung: SHARE Collaborative, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Pyridones, Drug Resistance, Viral. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare.
Abstract (Originalsprache)
Introduction
Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking. Integrase inhibitor (INI) resistance may limit future therapy. The optimal regimen is uncertain.
Methods
We synthesized evidence from PubMed, EMBASE, Cochrane and conference abstract databases through 18 November 2024, to identify observational cohort studies (OCS) that reported on VF events in virally suppressed individuals who switched to LA‐I CAB+RPV. We extracted data on VF, resistance‐associated mutations (RAMs) at VF, post‐VF regimen choice and re‐suppression. We assessed the risk of bias using a modified Downs and Black tool.
Results
VF definitions differed considerably among OCS, with 172 individuals experiencing VF across 79 cohorts that included 13 899 individuals. Twenty‐eight cohorts ( n = 7987) reported genotypic information at VF. Out of the 80 VF events with genotypic information available at the time of the VF event, NNRTI mutations were identified in 45 cases, INIs in 40 cases, and dual‐class resistance in 33 cases. Notably, 28 VF events were not accompanied by resistance. Post‐VF regimen choices were reported for 92 VF events. Regimens used were protease inhibitor (PI)‐based, oral INI‐based and some physicians continued LA‐I CAB+RPV post‐VF. Re‐suppression occurred in 87.8% (65/74) of VF events in which it was described.
Conclusions
In OCS, VF was a very uncommon occurrence and comparable with clinical trials. However, when it did occur, it was frequently accompanied by resistance. Post‐VF regimens used to achieve suppression varied, including LA‐I CAB+RPV maintenance and were highly successful.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SHARE Collaborative, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Barts Health NHS Trust, London, UK.
ORCID-Profile: Kyle Ring, Alexa Elias, Megan Devonald, Melanie Smuk, Chloe Orkin
Förderung
- ViiV Healthcare
Zitieren
APA
Ring, K., Elias, A., Devonald, M., Smuk, M., & Orkin, C. (2025). Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV. HIV Medicine. https://doi.org/10.1111/hiv.70057
Vancouver
Ring K, Elias A, Devonald M, Smuk M, Orkin C. Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV. HIV Medicine. 2025. doi:10.1111/hiv.70057
BibTeX
@article{Ring2025,
author = {Ring, Kyle and Elias, Alexa and Devonald, Megan and Smuk, Melanie and Orkin, Chloe},
title = {Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV},
journal = {HIV Medicine},
year = {2025},
doi = {10.1111/hiv.70057}
}
EUVIMED